Aviceda Therapeutics has launched biotech financing in 2025 with a $207.5m raise to advance its lead drug for geographic atrophy, a sight-threatening disease, into pivotal trials.
The Series C round, co-led by Omega Funds and TCGX, will support the ongoing phase 2/3 SIGLEC trial of AVD-104 for geographic atrophy linked to age-related macular degeneration.
The trial is expected to deliver results in the second half of the year, with funding also allocated to a phase 3 programme if progress stays on track.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The funding round also saw participation from investment firms including Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, and Digitalis Ventures.
Source: Pharmaphorum
Can’t stop reading? Read more
Exclusive Interview: Torge Barkholtz on rethinking SME succession through operator-led investing
Exclusive Interview: Torge Barkholtz on rethinking SME succession through operator-led investing...
Rightsizing the right way
Rightsizing the right way Rightsizing an organization is never easy. But, it is a normal process...
Mozaik Investments acquires majority stake in Romania’s Genesis College, plans €30m expansion
Mozaik Investments acquires majority stake in Romania’s Genesis College, plans €30m expansion...